Post-approval Study of NovoTTF-100A in Recurrent GBM Patients
Public ClinicalTrials.gov record NCT01756729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a non-randomized, concurrent control study, designed to confirm that the efficacy of the NovoTTF-100A System in patients with recurrent GBM treated in a real life settings following approval is comparable to that of BSC chemotherapy patients. The device is a portable, battery operated device that was approved for the treatment of adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically- or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.
Study identification
- NCT ID
- NCT01756729
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 13 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2012
- Primary completion
- Dec 31, 2017
- Completion
- Dec 31, 2017
- Last update posted
- Mar 1, 2016
2012 – 2018
United States locations
- U.S. sites
- 12
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294-0111 | — |
| Barrow Neurology Clinics | Phoenix | Arizona | 85013 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Keck Medical Center of USC | Los Angeles | California | 90033 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| University of Illinois at Chicago | Chicago | Illinois | 60612 | — |
| University of Kentucky, Markey Cancer Center | Lexington | Kentucky | 40536-0093 | — |
| Walter Reed National Military Medical Center | Bethesda | Maryland | 20889 | — |
| Washington University School of Medicine, Division of Oncology | St Louis | Missouri | 63110 | — |
| The Long Island Brain Tumor Center | Lake Success | New York | 11042 | — |
| Geisinger Health System | Danville | Pennsylvania | 17822 | — |
| Baylor Research Institute | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01756729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 1, 2016 · Synced Sep 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01756729 live on ClinicalTrials.gov.